Biosimilars Council weighs in on Matrix Global Advisors’ biosimilars report

The Biosimilars Council recently commented on a report released by Matrix Global Advisors, titled U.S. Biosimilars Market: Addressing Barriers to Success in the Second Decade, which recommends several policy and regulatory steps that would accelerate biosimilar competition and patient savings in their second decade of use.

“Today’s report highlights the immense opportunity and challenges facing biosimilar competition,” said Craig Burton, executive director of the Biosimilars Council. “Biosimilars provide lower prices and expand patient access to care, but policy and market barriers continue to stymie biosimilar competition. Policymakers must ensure a robust and sustainable biosimilar market by streamlining the FDA approval pathway, removing the unnecessary and confusing interchangeability designation, ensuring PBM coverage of new biosimilars, and reforming Medicare reimbursement policy for biosimilars.”

AAM: IRA hampers generic, biosimilar drug competition

The council pointed out that since March 2015, the FDA has approved 63 biosimilars and 42 have launched so far. The report from Matrix Global Advisors, authored by Alex Brill and Christy Robinson, outlines several recommendations to ensure a robust biosimilars competitive marketplace and patient savings, the Biosimilars Council said.

[Read more: AAM report: Generics, biosimilars generate $445B in savings]